Vivani Medical, Inc. (VANI) Stock Score, Valuation & Financial Research

Vivani Medical, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for VANI

Vivani Medical, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.24. These figures are a research snapshot, not a buy or sell recommendation.

What Vivani Medical, Inc. does

Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Vivani Medical is a clinical-stage biopharmaceutical company that focuses on the development of proprietary NanoPortal technology. It aims to generate future revenue by commercializing miniature, ultra long-acting subdermal drug implant candidates designed to address medication non-adherence and improve patient outcomes in chronic diseases.

Products and services

  • The company is currently in the development stage with a pipeline of drug implant candidates including NPM-139, NPM-133, NPM-115, and OKV-119.

Business relationships and partnerships

  • Okava Pharmaceuticals, Inc. — A collaboration for the development of the product candidate OKV-119. Source

Business strengths to evaluate

  • Proprietary NanoPortal technology platform Source
  • In-house research, development, and manufacturing capabilities Source

Business risks and research considerations

  • No anticipated revenue from product sales for the foreseeable future and potential for never achieving profitability Source
  • Uncertainty in developing or commercializing marketable products from the current pipeline Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

VANI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.24
Market capitalization:
106.93M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -26.31M
Free cash flow:
USD -25.49M
Cash:
USD 19.89M
Total debt:
USD 17.86M
EPS:
USD -0.35

What stands out

  • Free cash flow is USD -25.49M, negative for the stored period.
  • The balance sheet shows USD 19.89M of cash versus USD 17.86M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.04M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for VANI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can VANI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does VANI's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for VANI to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of VANI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research VANI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.